216 related articles for article (PubMed ID: 30529545)
1. Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.
Pippione AC; Sainas S; Goyal P; Fritzson I; Cassiano GC; Giraudo A; Giorgis M; Tavella TA; Bagnati R; Rolando B; Caing-Carlsson R; Costa FTM; Andrade CH; Al-Karadaghi S; Boschi D; Friemann R; Lolli ML
Eur J Med Chem; 2019 Feb; 163():266-280. PubMed ID: 30529545
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
[TBL] [Abstract][Full Text] [Related]
3. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
[TBL] [Abstract][Full Text] [Related]
5. Identification of 3,4-Dihydro-2
Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
[No Abstract] [Full Text] [Related]
6. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
Molecules; 2018 May; 23(6):. PubMed ID: 29794978
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydro-1H,5H-pyrazolo[1,2-a]pyrazole-1-carboxylates as inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Strašek N; Lavrenčič L; Oštrek A; Slapšak D; Grošelj U; Klemenčič M; Brodnik Žugelj H; Wagger J; Novinec M; Svete J
Bioorg Chem; 2019 Aug; 89():102982. PubMed ID: 31132601
[TBL] [Abstract][Full Text] [Related]
8. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
[TBL] [Abstract][Full Text] [Related]
9. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
Deng X; Kokkonda S; El Mazouni F; White J; Burrows JN; Kaminsky W; Charman SA; Matthews D; Rathod PK; Phillips MA
J Med Chem; 2014 Jun; 57(12):5381-94. PubMed ID: 24801997
[TBL] [Abstract][Full Text] [Related]
10. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.
Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF
J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313
[TBL] [Abstract][Full Text] [Related]
11. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
[TBL] [Abstract][Full Text] [Related]
12. CF
Agoni C; Salifu EY; Munsamy G; Olotu FA; Soliman M
Chem Biodivers; 2019 Dec; 16(12):e1900365. PubMed ID: 31589372
[TBL] [Abstract][Full Text] [Related]
13. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
[TBL] [Abstract][Full Text] [Related]
14. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
[TBL] [Abstract][Full Text] [Related]
17. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor.
Hurt DE; Widom J; Clardy J
Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):312-23. PubMed ID: 16510978
[TBL] [Abstract][Full Text] [Related]
18. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
[TBL] [Abstract][Full Text] [Related]
19. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Gujjar R; El Mazouni F; White KL; White J; Creason S; Shackleford DM; Deng X; Charman WN; Bathurst I; Burrows J; Floyd DM; Matthews D; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2011 Jun; 54(11):3935-49. PubMed ID: 21517059
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]